Conditions: HIV
Keywords: Pharmacokinetics Clinical Pharmacology Pharmacogenomics HIV
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 31
Healthy volunteers: yes

Brief summary:
This study evaluated the blood levels of atazanavir according to a genetic makeup for CYP3A5 (cytochrome P450 3A5, an enzyme that metabolizes atazanavir). The hypothesis was that people with a slow-metabolizing genotype would have higher blood levels of atazanavir compared to people with the normal metabolizing genotype.

Detailed description:

Arms:
arm 1: A pre-screening genetic test determines CYP3A5 expressor status arm 2: A pre-screening genetic test determines CYP3A5 non-expressor status

Interventions: intervention 1: Atazanavir
Intervention descriptions: intervention 1: Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days

Protocol document: